Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.

Data from a pooled analysis including the DECLARE-TIMI 58 trial, the SOLOIST-WHF, and SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) trials showed borderline significant reduction in the composite outcome of HF hospitalization or cardiovascular death. 31 EMPEROR-PRESERVED (Enpagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction), in which 11% of the patients were Asians, enrolled 5,988 patients with HFpEF with and without T2DM.

also in 11,409 other papers